ConductScience.org, home

Paper34482769

Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials.

Asif B and 1 other. Expert Opin Investig Drugs, 2022. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials. Papers, record 34482769. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34482769

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials.
PubMed
Journal
Expert Opin Investig Drugs
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.45
iCite
Revised in PubMed
2026-07-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Asif BBilal
2Koh CChristopherhttps://orcid.org/0000-0002-4755-5607

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Hepatitis DMajor topic
Hepatitis D, ChronicMajor topic
Liver NeoplasmsMajor topic
Hepatitis B virus
Hepatitis Delta Virus
Humans

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z99 DK999999Intramural NIH HHSUnited StatesZ99DK999999PubMedNIH RePORTER
ZIA DK075150Intramural NIH HHSUnited StatesZIADK075150PubMedNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03852433Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)Background

Source ClinicalTrials.gov

Download CSV of trials

References114

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18116240Isoprenylation of large hepatitis delta antigen is necessary but not sufficient for hepatitis delta virus assembly.Virology1994https://conductscience.org/library/papers/8116240PubMed
216495266Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides.Antimicrob Agents Chemother2006https://conductscience.org/library/papers/16495266PubMed
326897654Pathogenesis by subviral agents: viroids and hepatitis delta virus.Curr Opin Virol2016https://conductscience.org/library/papers/26897654PubMed
42481341Mechanisms of action of interferons.Semin Liver Dis1989https://conductscience.org/library/papers/2481341PubMed
58617711The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells.J Biol Chem1996https://conductscience.org/library/papers/8617711PubMed
615613342Roles of carboxyl-terminal and farnesylated residues in the functions of the large hepatitis delta antigen.J Virol2005https://conductscience.org/library/papers/15613342PubMed
716959288The human RNA polymerase II interacts with the terminal stem-loop regions of the hepatitis delta virus RNA genome.Virology2007https://conductscience.org/library/papers/16959288PubMed
832398799Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg.Sci Rep2020https://conductscience.org/library/papers/32398799PubMed
927880976A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians.Hepatology2017https://conductscience.org/library/papers/27880976PubMed
1025098971Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.Hepatology2014https://conductscience.org/library/papers/25098971PubMed
113794405Titration of the infectivity of hepatitis D virus in chimpanzees.J Infect Dis1987https://conductscience.org/library/papers/3794405PubMed
1233099752Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.Hepatol Int2020https://conductscience.org/library/papers/33099752PubMed
1330562970A Divergent Hepatitis D-Like Agent in Birds.Viruses2018https://conductscience.org/library/papers/30562970PubMed
1416443667Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar).Drug Metab Dispos2006https://conductscience.org/library/papers/16443667PubMed
156934539delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees.Proc Natl Acad Sci U S A1980https://conductscience.org/library/papers/6934539PubMed
1630833068Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.Lancet Infect Dis2019https://conductscience.org/library/papers/30833068PubMed
1722932972Treatment of chronic delta hepatitis.Semin Liver Dis2012https://conductscience.org/library/papers/22932972PubMed
183762705Structure, sequence and expression of the hepatitis delta (delta) viral genome.Nature1986https://conductscience.org/library/papers/3762705PubMed
1921268724Peginterferon plus adefovir versus either drug alone for hepatitis delta.N Engl J Med2011https://conductscience.org/library/papers/21268724PubMed
2030228220Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis.Gut2019https://conductscience.org/library/papers/30228220PubMed

See all 114 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42875707The Economic Burden of HDV in Italy: Evaluating the Potential Impact and Effects of Bulevirtide for Chronic HDV Infection.Clin Drug Investig2026https://conductscience.org/library/papers/42875707PubMed
42828159Therapeutic, preventive, and pathogenetic advances in viral hepatitis.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42828159PubMed
40006617Clinical Pharmacology of Bulevirtide: Focus on Known and Potential Drug-Drug Interactions.Pharmaceutics2025https://conductscience.org/library/papers/40006617PubMed
36712949Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.Drug Des Devel Ther2023https://conductscience.org/library/papers/36712949PubMed
36621853Diagnosis of HDV: From virology to non-invasive markers of fibrosis.Liver Int2023https://conductscience.org/library/papers/36621853PubMed
36519386Epidemiology, presentation, and therapeutic approaches for hepatitis D infections.Expert Rev Anti Infect Ther2023https://conductscience.org/library/papers/36519386PubMed
35632728Hepatitis B Virus-Associated Hepatocellular Carcinoma.Viruses2022https://conductscience.org/library/papers/35632728PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34482769

GET https://conductscience.org/api/papers/v1/34482769/references?page=2